Ajay K. Gopal
M.D., Emory University, Medicine, 1993.
B.S., Duke University, Zoology, 1989.
American Association for Cancer Research
American Society for Clinical Oncology
American Society of Hematology
2003-2007, Assistant Member, Fred Hutchinson Cancer Research Center, Clinical Research Division
2003-2007, Assistant Professor, University of Washington, School of Medicine, Medicine, Oncology
1997-2000, Fellow in Medical Oncology, University of Washington, School of Medicine, Medicine, Oncology
1993-1996, Resident in Internal Medicine, Duke University, Duke University Medical Center, Medicine
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma.. The New England journal of medicine.. 2014.
Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Aged ≥ 60 Years with B-Cell Lymphoma.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2014.
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(9):1403-6.. 2013.
Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(3):314-20.. 2013.
A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP-Rituximab versus CHOP + 131Iodine--Tositumomab.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(23):6624-32.. 2013.
CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody-Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies.. Journal of clinical pharmacology. 53(8):866-77.. 2013.
131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.. Nuclear medicine communications. 33(12):1225-31.. 2012.
Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation.. The Korean journal of hematology. 47(1):8-16.. 2012.
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(18):2183-2189.. 2012.
Allogeneic hematopoietic cell transplantation in mantle cell lymphoma.. Best practice & research. Clinical haematology. 25(2):165-74.. 2012.
The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells.. Journal of clinical apheresis.. 2012.
Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(10):1537-45.. 2011.
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(9):1190-7.. 2011.
Blood-based detection of radiation exposure in humans based on novel phospho-Smc1 ELISA.. Radiation research. 175(3):266-81.. 2011.